Belatacept
Nulojix (belatacept) is a protein pharmaceutical. Belatacept was first approved as Nulojix on 2011-06-15. It has been approved in Europe to treat graft rejection and kidney transplantation. The pharmaceutical is active against T-lymphocyte activation antigen CD80 and T-lymphocyte activation antigen CD86.
| Trade Name | Nulojix |
|---|---|
| Common Name | Belatacept |
| Indication | graft rejection, kidney transplantation |
| Drug Class | Receptor molecules, native or modified: T-cells |
